Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-075 · 1 trial · 8 indications
Maximum tolerated dose is defined as the highest dose level at which less than 2 of 6 participants experience the same dose limiting toxicity. If more than 2 participants experience a different dose limiting toxicity, the maximum tolerated dose may be further evaluated or determined to be exceeded based on discussions with the investigators and medical monitors.
Area under the plasma concentration versus time curve from time 0 (pre-dose) to the time of the last measurable concentration (AUC 0-t).
| Arm | Type | Description |
|---|---|---|
| ABBV-075 | EXPERIMENTAL | Dose escalation cohorts of ABBV-075 monotherapy |
| ABBV-075 and venetoclax combination | EXPERIMENTAL | Expansion cohorts of ABBV-075 and venetoclax combination therapy |
| ABBV-075 expansion | EXPERIMENTAL | Expansion cohorts of ABBV-075 monotherapy |
| Name | Type | Description |
|---|---|---|
| ABBV-075 | DRUG | ABBV-075 Oral tablets |
| Venetoclax | DRUG | Venetoclax tablets, film-coated |
Inclusion Criteria: 1. Participant in the dose escalation cohorts must have histological confirmation of locally advanced or metastatic solid tumor that is either refractory after standard of care therapy for the disease or for which standard of care therapy or does not exist. 2. Participants in th...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
ABBV-075 is an investigational small molecule being developed for the treatment of cancer. It has been studied in patients with various cancer types, including breast cancer, non-small cell lung cancer, acute myeloid leukemia, multiple myeloma, prostate cancer, small cell lung cancer, and non-Hodgkin lymphoma.
ABBV-075 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The drug is an investigational small molecule in the oncology therapeutic area.
ABBV-075 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to evaluate its safety and pharmacokinetics in patients with cancer.
ABBV-075 has been studied in one clinical trial, identified as NCT02391480, titled "A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer." This Phase 1 trial was completed in the United States and enrolled 128 participants aged 18 years and older.
ABBV-075 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial. The trial was designed to evaluate safety and pharmacokinetics, and the drug remains in clinical development for the treatment of cancer.